TORL Biotherapeutics LLC
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2018-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.torlbio.com
Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
- Conditions
- Epithelial Ovarian CancerPrimary PeritonealFallopian Tube CancerEndometrioid Ovarian Cancer
- Interventions
- First Posted Date
- 2024-11-15
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 230
- Registration Number
- NCT06690775
- Locations
- 🇺🇸
SCRI - Arizona Oncology Associates, PC-HOPE, Tucson, Arizona, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
A Phase 1, First in Human Study of TORL-4-500 in Patients with Advanced Cancer
- Conditions
- Advanced Solid TumorHepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT06005740
- Locations
- 🇺🇸
Mayo Clinic Phoenix, Phoenix, Arizona, United States
🇺🇸Providence Medical Foundation, Fullerton, California, United States
🇺🇸UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
First in Human Study of TORL-3-600 in Participants With Advanced Cancer
- First Posted Date
- 2023-07-17
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT05948826
- Locations
- 🇺🇸
Providence Medical Foundation, Fullerton, California, United States
🇺🇸Sarah Cannon Research Institute, Denver, Colorado, United States
🇺🇸Fort Wayne Medical Oncology and Hematology Inc., Fort Wayne, Indiana, United States
First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer
- Conditions
- Gastric CancerAdvanced Solid TumorPancreas CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT05159440
- Locations
- 🇺🇸
Providence St. Jude Medical Center, Fullerton, California, United States
🇺🇸UCLA - JCCC Clinical Research Unit, Los Angeles, California, United States
🇺🇸Torrance Memorial Medical, Torrance, California, United States
First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
- Conditions
- Gastric CancerPancreas CancerAdvanced Solid TumorGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2021-12-14
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- TORL Biotherapeutics, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT05156866
- Locations
- 🇺🇸
Texas Oncology-Austin, Austin, Texas, United States
🇺🇸Texas Oncology-Dallas, Dallas, Texas, United States
🇺🇸Texas Oncology-Tyler, Tyler, Texas, United States
- Prev
- 1
- 2
- Next